Click Here to return To Results

 

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis NEJM 354:899-910,965, Polman,C.H.,et al, 2006 See this aricle in Pubmed Article Abstract Natalizumab reduced the risk of the sustained progression of disability and the rate of clinical relapse in patients with relapsing multiple sclerosis. Adhesion-molecule inhibitors hold promise as an effective treatment for relapsing multiple sclerosis.

Related Tags

(click to filter results - removes previous filter) adverse drug reaction disability,neurological immunosuppression immunosuppressive agents monoclonal antibodies MRI MRI,abnormal MRI,serial multiple sclerosis multiple sclerosis,relapsing multiple sclerosis,treatment of natalizumab treatment of neurologic disorder

Click Here to return To Results